Dr. Karl B. Scheidweiler
Chief Toxicologist
Connect Online with this Speaker

Karl B. Scheidweiler earned his Ph.D. in Pathology from the University of Rochester in 2002 after completing his research dissertation on “Pharmacokinetics and actions of methylecgonidine, a component of crack cocaine smoke.” He worked as a Post-doctoral Fellow for Marilyn A. Huestis, Ph.D. at the National Institute on Drug Abuse, National Institutes of Health (NIDA-NIH) from 2002-2006 and served as a Staff Scientist at NIDA-NIH until 2016. During his tenure at NIDA-NIH, Dr. Scheidweiler developed and validated gas chromatography-mass spectrometry and liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for numerous drug classes in various matrices, including oral fluid, to support Intramural Research Board (IRB)-approved controlled drug administration clinical pharmacokinetic/pharmacodynamic research studies. These clinical research studies provided data to assist interpretation of workplace, drug treatment and driving under the influence of drugs (DUID) cases. Dr. Scheidweiler served as an R&D Scientist from 2016-2020 developing LC-MS/MS methods for Prescription Drug Monitoring Toxicology laboratories at Quest Diagnostics. Since 2020, Dr. Scheidweiler has worked for Abbott (Immunalysis) in a Chief Toxicologist/Scientific Affairs role supporting development of various Toxicology products including urine and oral fluid screening immunoassays.